STOP PKD

SGLT2 inhibition for the treatment of polycystic kidney disease

About the project What's ADPKD?

What is STOP PKD about?

The STOP-PKD study is investigating a new treatment option for people with autosomal dominant polycystic kidney disease (ADPKD). The study aims to determine whether an already approved medication from the class of so-called SGLT2 inhibitors (dapagliflozin) can have a positive effect on the course of ADPKD.

What is ADPKD?

ADPKD is a hereditary condition characterised by the formation of numerous small cysts (fluid-filled sacs) in the kidneys. Over time, these cysts grow, causing the kidneys to gradually lose their function. Those affected often require dialysis or a kidney transplant by middle age.